SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  European Journal of Pharmacology

• Publication date

  2014-03-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejphar.2014.01.040PMID 24486393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.

  2013influential reference
• Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study

  2013cited by this paper
• Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose‐finding study

  2013cited by this paper
• A Phase IIb, randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

  2013cited by this paper
• Body Fat Distribution and Risk of Cardiovascular Disease: An Update

  2012cited by this paper
• Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.

  2012cited by this paper
• Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences.

  2012cited by this paper
• Brain Glucose Sensors Play a Significant Role in the Regulation of Pancreatic Glucose-Stimulated Insulin Secretion

  2012cited by this paper
• Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

  2012cited by this paper
• Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet‐Induced Obese (DIO) Rats

  2012cited by this paper
• Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.

  2012cited by this paper
• Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.

  2012influential reference
• SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function

  2011cited by this paper
• Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

  2011influential reference
• Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

  2011cited by this paper
• Secreted proteins from adipose tissue and skeletal muscle – adipokines, myokines and adipose/muscle cross-talk

  2011cited by this paper
• Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?

  2011cited by this paper
• Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise

  2010cited by this paper
• SGLT2 mediates glucose reabsorption in the early proximal tubule

  2010cited by this paper
• Diabesity: therapeutic options

  2010cited by this paper
• Validation of Computed Tomographic Estimates of Intra‐abdominal and Subcutaneous Adipose Tissue in Rats and Mice

  2010cited by this paper
• Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

  2010cited by this paper
• Obesity-related hypertension.

  2009cited by this paper
• The role of the sympathetic nervous system in obesity-related hypertension

  2009cited by this paper
• In vivo quantification of subcutaneous and visceral adiposity by micro-computed tomography in a small animal model.

  2009cited by this paper
• Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats.

  2008cited by this paper
• Metabolic cycling in control of glucose-stimulated insulin secretion.

  2008cited by this paper
• Brain glucose sensing, counterregulation, and energy homeostasis.

  2007cited by this paper
• Active sugar transport in health and disease

  2007cited by this paper
• Diazoxide attenuates insulin secretion and hepatic lipogenesis in zucker diabetic fatty rats.

  2005cited by this paper
• Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)

  2002cited by this paper
• Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications

  1995influential reference
• Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter.

  1992cited by this paper
• Estimation of energy expenditure, net carbohydrate utilization, and net fat oxidation and synthesis by indirect calorimetry: evaluation of errors with special reference to the detailed composition of fuels.

  1988influential reference
• The effect of diazoxide-induced hormonal secretion on plasma triglyceride concentration in the rat

  1980cited by this paper
• Animal models for the study of energy balance

  1980cited by this paper

• SGLT2 inhibitor-induced glycosuria improves steatotic liver disease in parallel with enhanced ureagenesis in ob/ob mice.

  2026cites this paper
• Targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Available and Future Pharmaceutical Options

  2025cites this paper
• The Impact of Sodium-Glucose Co-Transporter-2 Inhibition on Insulin Resistance and Inflammation in Patients with Type 2 Diabetes: A Retrospective Study

  2025cites this paper
• Combination therapy with vitamin E and ertugliflozin in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a randomized clinical trial

  2025cites this paper
• SGLT2 Inhibitors and the Risk of Infections in Type 2 Diabetes: Systematic Review and Meta-Analyses of Real-World Evidence

  2025cites this paper
• Effect of empagliflozin on liver fibrosis and steatosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized clinical trial

  2025cites this paper
• Current and Emerging Treatments for Metabolic Associated Steatotic Liver Disease and Diabetes: A Narrative Review

  2025cites this paper
• Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy

  2025cites this paper
• Effects of Hypoglycemic Agents on The Musculoskeletal System: A Comprehensive Review

  2025cites this paper
• Recent Advances in Perioperative Care of Patients using New Antihyperglycaemic Drugs and Devices Dedicated to Diabetes.

  2024cites this paper
• Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study

  2024cites this paper
• Exogenous Ketones in Cardiovascular Disease and Diabetes: From Bench to Bedside

  2024cites this paper
• SGLT‐2 Inhibitor Use and Cause‐Specific Hospitalization Rates: An Outcome‐Wide Study to Identify Novel Associations of SGLT‐2 Inhibitors

  2024cites this paper
• The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial

  2024cites this paper
• The effect of antidiabetic drugs on bone metabolism: a concise review

  2024cites this paper
• Therapeutic Approaches for Nonalcoholic Fatty Liver Disease: Established Targets and Drugs

  2023cites this paper
• Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials

  2023cites this paper
• Sodium-Glucose Cotransporter 2 Inhibitor-induced Ketoacidosis and Non-Ketotic Acidosis: When Is There a Role for Bicarbonate?

  2023cites this paper
• Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome

  2023cites this paper
• Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study

  2023cites this paper
• Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors

  2023cites this paper
• Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review.

  2023cites this paper
• Association between Obstructive Sleep Apnea and Heart Failure in Adults—A Systematic Review

  2023cites this paper
• SGLT‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model

  2023cites this paper
• The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?

  2023cites this paper
• The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review

  2023cites this paper
• Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications.

  2023cites this paper
• Effect of Canagliflozin on liver steatosis in obese non diabetic patients with non-alcoholicfatty liver disease: A double blind randomized controlled trial

  2023influential citation
• Sodium-dependent Glucose Co-Transporter-2 Inhibitor Empagliflozin Exerts Neuroprotective Effects in Rotenone-Induced Parkinson's Disease Model in Zebrafish; Mechanism Involving Ketogenesis and Autophagy.

  2023cites this paper
• Empagliflozin improves cardiac function in rats with chronic heart failure

  2023cites this paper
• Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials.

  2023cites this paper
• Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms.

  2023cites this paper
• An Assessment Article on the Cure of Sarcopenia and its Association with type 2 Diabetes in the Elderly

  2023cites this paper
• Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets

  2023cites this paper
• Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling

  2022cites this paper
• Research Progress in the Effect Evaluation of GLP1-1 Agonists

  2022cites this paper
• Sodium-Glucose Co-Transporter-2 Inhibitors and Epicardial Adiposity.

  2022cites this paper
• Effect of sodium–glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis

  2022cites this paper
• Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes

  2022cites this paper
• The Role of SGLT2 Inhibitor Ipragliflozin on Cardiac Hypertrophy and microRNA Expression Profiles in a Non-diabetic Rat Model of Cardiomyopathy.

  2022cites this paper
• DMSO_A_375559 2583..2597

  2022cites this paper
• The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors

  2022cites this paper
• Effects of sodium-glucose co-transporter-2 inhibitors on anthropometric indices and metabolic markers in overweight/obese individuals without diabetes: a systematic review and meta-analysis

  2022cites this paper
• Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors.

  2022cites this paper
• Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma

  2022cites this paper
• SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection

  2022cites this paper
• Loss of function of renal Glut2 reverses hyperglycaemia and normalises body weight in mouse models of diabetes and obesity

  2022cites this paper
• Effects of dapagliflozin on adipose and liver fatty acid composition and mRNA expression involved in lipid metabolism in high-fat-fed rats.

  2022cites this paper
• IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW

  2022cites this paper
• SGLT2 Inhibitors and Ketone Metabolism in Heart Failure

  2022cites this paper
• Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress

  2021cites this paper
• Discovery of ACH-000143: A Novel Potent and Peripherally Preferred Melatonin Receptor Agonist that Reduces Liver Triglycerides and Steatosis in Diet-Induced Obese Rats.

  2021cites this paper
• Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trial

  2021cites this paper
• Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy.

  2021cites this paper
• The Effects of SGLT2 Inhibitors on Lipid Metabolism

  2021cites this paper
• SGLT2 inhibition for cardiovascular diseases, chronic kidney disease and NAFLD.

  2021cites this paper
• Proposed mechanisms of systemic cardiovascular action of gliflosins

  2021cites this paper
• Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis

  2021cites this paper
• Cardio-Renal Benefits of SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Mechanisms and Clinical Evidence.

  2021cites this paper
• Monthly Volume 12 Number 1 January 15 , 2021 ABOUT COVER

  2021cites this paper
• Novel glucose-lowering drugs for non-alcoholic fatty liver disease

  2021cites this paper
• The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non‐alcoholic fatty liver disease

  2021cites this paper
• Nanotechnology in Diagnosis and Treatment of Diabetes Mellitus: Review

  2021influential citation
• Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: A Systematic Review and a Meta-Analysis

  2021cites this paper
• Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.

  2021cites this paper
• Effects of dapagliflozin on peripheral sympathetic nerve activity in standard chow- and high-fat-fed rats after a glucose load.

  2021cites this paper
• Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class

  2021cites this paper
• Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications

  2021cites this paper
• Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks

  2020cites this paper
• SGLT2 Inhibitors and the Mechanisms Involved in Weight Loss

  2020cites this paper
• Update on: effects of anti-diabetic drugs on bone metabolism

  2020cites this paper
• Dapagliflozin restores insulin and growth hormone secretion in obese mice.

  2020cites this paper
• SGLT2-Inhibitoren bei diabetischer Nephropathie

  2020cites this paper
• Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice

  2020cites this paper
• Effects of sodium–glucose cotransporter 2 inhibitors on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials

  2020cites this paper
• Link between body weight changes and metabolic parameters in drugs naïve subjects with type 2 diabetes treated with canagliflozin monotherapy

  2020cites this paper
• Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials

  2020cites this paper
• Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?

  2020cites this paper
• The use of sodium‐glucose co‐transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?

  2020cites this paper
• Diet intake control is indispensable for the gluconeogenic response to sodium–glucose cotransporter 2 inhibition in male mice

  2020cites this paper
• Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet‐fed streptozotocin‐treated diabetic rats

  2020cites this paper
• Obesity Mediates Apoptosis and Extracellular Matrix Metabolic Imbalances via MAPK Pathway Activation in Intervertebral Disk Degeneration

  2019cites this paper
• Does Dapagliflozin Affect Energy Intake and Appetite? A Randomized, Controlled Exploratory Study in Healthy Subjects

  2019cites this paper
• Fighting type-2 diabetes: present and future perspectives.

  2019cites this paper
• Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results).

  2019cites this paper
• Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes

  2019cites this paper
• Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease

  2019cites this paper
• Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity

  2019cites this paper
• Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats

  2019cites this paper
• SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

  2019cites this paper
• Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study

  2019cites this paper
• The efficacy and safety of velagliflozin over 16 weeks as a treatment for insulin dysregulation in ponies

  2019cites this paper
• Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study

  2019cites this paper
• Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities

  2019cites this paper
• Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

  2019cites this paper
• A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors

  2019cites this paper
• Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet.

  2019cites this paper
• Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy.

  2019cites this paper
• The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1

  2019cites this paper
• SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions

  2019cites this paper